Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market - Regional Insights
Regional segmentation of the global fibrodysplasia ossificans progressiva (FOP) treatment market by Coherent Market Insights includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America holds a dominant position in the global fibrodysplasia ossificans progressiva (FOP) treatment market owing to the increasing research and development activities. For instance, on January 2020, Regeneron Pharmaceuticals, Inc., an American pharmaceutical company, released the results from a Phase 2, double-blind placebo-controlled trial, LUMINA-1, the trial was initiated to evaluate garetosmab (REGN2477) for the treatment of fibrodysplasia ossificans progressiva.
Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients